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A patient with lower-limb onset ALS presented with a one-month history of vasovagal episodes and
a one-week history of cough productive of green sputum and lethargy. She was drowsy and in acute on
chronic type-two respiratory failure. She responded to non-invasive ventilation, however she suffered
recurrent episodes of profound bradycardia on removal of the mask, which gradually resolved over ten
days. We have reviewed the literature and offer a potential explanation for these events.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Case
A 53 year-old woman with a 3.7-year history of progressive
lower-limb weakness due to amyotrophic lateral sclerosis (ALS),
conﬁrmed two years previously, was admitted with a one-month
history of episodes of dizziness, some of which were associated
with brief loss of consciousness. She was noted to be pale during
these events and at least one episode occurred on laughing. She
was incontinent during a few events, but always fully recovered
within minutes. She had a cough productive of green sputum for
one week and on examination she was drowsy with poor respira-
tory effort. She was wheelchair bound with global ﬂaccid weakness
in the lower limbs, mild upper limbweakness and very mild bulbar
impairment.
Arterial blood gases showed acute on chronic type-two respi-
ratory failure (pH ¼ 7.17, PaCO2 ¼ 15.1 kPa) and her chest radio-
graph showed bibasal atelectasis. Non-invasive ventilation (NIV)
was initiated together with a seven-day course of amoxicillin. She
improved clinically and physiologically with rapid correction of the
respiratory acidosis. However, she suffered profound bradycardia,
sometimes associated with transient loss of consciousness, on each
occasion the NIVmaskwas removed (Fig.1), in the early stages after
initiation of NIV. The episodes of bradycardia resolved when NIV
was recommenced.C. Echevarria).
-NC-ND license.She was taking a number of medications that could potentially
induce bradycardia: atenolol, diltiazem, ranitidine (cimetidine has
been shown to cause bradycardia), and quinine. These were dis-
continued, but the frequency and severity of the episodes of
bradycardia were unaffected. The episodes of bradycardia occurred
too rapidly for hypoxia to be implicated as the cause and they
persisted after correction of the initial respiratory acidosis. There
was no evidence of myocardial infarction or an intrinsic conduction
abnormality on her ECG.
The episodes of bradycardia were fully blocked by pre-treatment
with atropine before removal of the mask (Fig. 1). Subsequently, an
isoprenaline infusion was commenced with similar efﬁcacy. The
dose of isoprenaline was gradually titrated down and we were able
to discontinue treatmentwithout recurrence of the bradycardia after
ten days. The patient was discharged home on long-term non-
invasive ventilation and survived for a further two years and two
months without any subsequent rhythm disturbance.
2. Discussion
To our knowledge, bradycardia on interruption of NIV has not
been previously reported. Robert et al.1 describe similar episodes of
bradycardia when attempting to wean intubated and ventilated
patients with Adult Respiratory Distress Syndrome (ARDS). The
episodes of bradycardia occurred during the recovery phase and
resolved over two to nine days, similar to our observation. They
proposed two potential mechanisms: Firstly, stimulation of the
vagally-mediated high-pressure arterial baroreﬂex (A reduction in
Fig. 1. ECG showing bradycardia on removal of NIV, followed by ECG in which
bradycardia was prevented with atropine.
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stoke volume. Both reduced extra-vascular thoracic pressure and
increased stroke volume serve to increase transmural pressure
across the aorta, stimulating the high-pressure baroreﬂex and thus
bradycardia). Secondly, they suggest an imbalance between
sympathetic and parasympathetic tone. As all events occurred in
the recovery phase this is plausible; the arterial high-pressure
baroreﬂex would be offset by high sympathetic tone when the
patient was acutely ill, but not during the recovery phase as
sympathetic tone fell back towards normal levels. However, this
does not explain why the events subsequently resolved.
We propose a similar mechanism and, in addition, suggest
down-regulation of adrenergic receptors during the period of high
sympathetic tone, with subsequent restoration of receptor activity
as sympathetic tone fell towards normal. The patient would be
more susceptible to vagally mediated bradycardia in response to
stimulation of the arterial baroreﬂex after sympathetic tone had
fallen towards normal levels from a previously elevated state, but
before up-regulation of adrenergic receptors had occurred.
In the case we described, the occurrence of vasovagal syncope in
the weeks before the patient’s acute decompensation may be
explained by diurnal variation in sympathetic tone, which would
have been higher at night due to severe sleep disordered breathing,
hypoventilation and consequent arousals,2 falling subsequently
during the day. To assess the effects of sleep-disordered breathing on
sympathetic tonewemeasured overnight urinary catecholamines in
18 subjectswithALSpresentingwithorthopnoeaorhypercapnia, due
to respiratorymuscleweakness. Catecholamine levels were elevated
in 14 subjects; mean (SD) noradrenaline ¼ 84 (49) nmol/mmol
creatinine. High catecholamine levels are also seen in obstructive
sleep apnoea (OSA) and fall immediately following initiation of CPAP
therapy3e5 further supporting our hypothesis: this may occur after
one overnight treatment.
Persistent catecholamine stimulation results in the down-
regulation of adrenergic receptors. Cases et al. showed down-
regulation of beta-2 receptors on lymphocytes in humans with
phaeochromacytoma, which reverted to normal within four-weeks
of tumour removal.6 Ratge et al. had similar ﬁndings but showed
an initial prompt restoration (within hours to a few days) and then
a one- to two-month improvement in the beta-2 adrenergic systemon lymphocytes.7 Other work has shown down-regulation of adre-
noreceptors in phaeochromacytoma as a consequence of catechol-
amines in rat renal cortices8,9 and rat hearts.10e12
In phaeochromocytoma there are often extremely high levels of
catecholamines. However, endogenous down-regulation has been
seen in humans at more normal physiological levels. Beta-2 adren-
ergic receptor down-regulation has been documented in the muscle
biopsy of healthy individuals who are overtrained (they had a non-
signiﬁcant increase in nocturnal urinary epinephrine).13 Alpha-2 and
beta-2 adrenoreceptor down-regulation has been demonstrated on
platelets and lymphocytes of marathon runners in the presence of
increased catecholamine levels.14
Catecholamine and beta-adrenergic receptor levels have not been
studied in patientswith ALS before and after initiation of NIV. Sudden
circulatorycollapsehasbeen reported in invasivelyventilatedpatients
with amyotrophic lateral sclerosis,15 which may have been related to
autonomic dysfunction. In these patients the blood pressure response
to noradrenaline infusionwas poor, consistent with down-regulation
of adrenoreceptors induced by the constant sympathetic hyperac-
tivity. Shimizu et al. have shown down-regulation of alpha adrenor-
eceptors in the peripheral blood vessels of ventilated ALS patients,
whilst examining blood pressure dysfunction. Of note, these cases
differ from our own observation as our patient only suffered episodes
of profound bradycardia when NIV was interrupted. Whilst this
appears to be a relatively uncommon phenomenon, it settled with
conservative management. Awareness of this occurrence and its
natural history may avoid unnecessary pacemaker insertion and is
relevant to respiratory physicians, cardiologists, neurologists and
intensivists alike.
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